Lugano, Switzerland, 21 September 2022 – Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets, announces that two […]

Lugano, Switzerland, September 8, 2022 – Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets, in conjunction […]

Lugano, Switzerland, September 1, 2022 – Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record […]

Lugano, Switzerland, August 8, 2022 – Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets, announces its […]

Lugano, Switzerland, June 02, 2022 – Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets, announces its […]

New R&D hub will be based at U.S. subsidiary, Helsinn Therapeutics (U.S.), Inc. (HTU) and will support clinical work across Helsinn Group’s diversified pipeline of […]

Lugano, Switzerland, May 19, 2022 – Helsinn Group, a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record […]

MONTREAL, Quebec and LUGANO, Switzerland – May 12, 2022 – Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, and Helsinn Healthcare […]

Lugano, Switzerland, May 11, 2022 – Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets, is pleased […]

Lugano, Switzerland, and Singapore, 04 May 2022 – Juniper Biologics Pte Ltd , a science-led healthcare company focused on researching, developing and commercializing novel therapies,and […]